1-7 of 7
Toshinori Agatsuma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models

Hirokazu Suzuki, Shotaro Nagase, Chiemi Saito, Atsuko Takatsuka, Motoko Nagata, Kokichi Honda, Yuki Kaneda, Yumi Nishiya, Tomoyo Honda, Tomomichi Ishizaka, Kensuke Nakamura, Takashi Nakada, Yuki Abe, Toshinori Agatsuma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (3): 257–271.
https://doi.org/10.1158/1535-7163.MCT-23-0287
Published: 04 March 2024
View articletitled, Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
Open the PDF for Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models in another window
Includes: Supplementary data
Journal Articles

DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models

Michiko Yamato, Jun Hasegawa, Takanori Maejima, Chiharu Hattori, Kazuyoshi Kumagai, Akiko Watanabe, Yumi Nishiya, Tomoko Shibutani, Tetsuo Aida, Ichiro Hayakawa, Takashi Nakada, Yuki Abe, Toshinori Agatsuma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 635–646.
https://doi.org/10.1158/1535-7163.MCT-21-0554
Published: 01 April 2022
View articletitled, DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models
Open the PDF for DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

Daisuke Okajima, Satoru Yasuda, Takanori Maejima, Tsuyoshi Karibe, Ken Sakurai, Tetsuo Aida, Tadashi Toki, Junko Yamaguchi, Michiko Kitamura, Reiko Kamei, Tomomichi Fujitani, Tomoyo Honda, Tomoko Shibutani, Sumie Muramatsu, Takashi Nakada, Riki Goto, Shu Takahashi, Miki Yamaguchi, Hirofumi Hamada, Yutaka Noguchi, Masato Murakami, Yuki Abe, Toshinori Agatsuma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12): 2329–2340.
https://doi.org/10.1158/1535-7163.MCT-21-0206
Published: 01 December 2021
View articletitled, Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells
Open the PDF for Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells in another window
Includes: Supplementary data
Journal Articles

Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models

Daisuke Okajima, Junko Yamaguchi, Michiko Kitamura, Reiko Kamei, Takanori Maejima, Tomoko Shibutani, Satoru Yasuda, Tadashi Toki, Tsuyoshi Karibe, Tomomichi Fujitani, Takashi Nakada, Riki Goto, Yutaka Noguchi, Yuki Abe, Toshinori Agatsuma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C026.
https://doi.org/10.1158/1535-7163.TARG-19-C026
Published: 01 December 2019
View articletitled, Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
Journal Articles

Abstract B095: Novel anti-CD147 antibodies inducing activation of SMAD signaling and tumor shrinkage in intractable cancer models

Keisuke Fukuchi, Kayoko Nanai, Shoji Yamamoto, Jun Tsukada, Yusuke Totoki, Koichiro Inaki, Masato Ishigami, Naoyuki Makita, Yoko Nakano, Chigusa Yoshimura, Kozo Yoneda, Masato Amano, Kensuke Nakamura, Yoshiyuki Kanari, Yoko Oda, Haruyuki Nishigohri, Rika Nakano, Atsuko Nishida, Kenji Murakami, Yumi Matsui, Naomi Kasanuki, Shoji Midori, Satoko Funo, Sayako Takahashi, Hironobu Komori, Toshiaki Ohtsuka, Toshinori Agatsuma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B095.
https://doi.org/10.1158/1535-7163.TARG-19-B095
Published: 01 December 2019
View articletitled, Abstract B095: Novel anti-CD147 antibodies inducing activation of SMAD signaling and tumor shrinkage in intractable cancer models
Journal Articles

Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity

René Bartz, Keisuke Fukuchi, Toshiaki Ohtsuka, Tanja Lange, Katrin Gruner, Ichiro Watanabe, Shinko Hayashi, Yoko Oda, Reimi Kawaida, Hironobu Komori, Yoshinori Kashimoto, Peter Wirtz, Jan-Peter A. Mayer, Mauricio Redondo-Müller, Shuntaro Saito, Mizuki Takahashi, Hiroyuki Hanzawa, Emi Imai, Alberto Martinez, Masaharu Hanai, Dieter Häussinger, Roger W. Chapman, Toshinori Agatsuma, Johannes Bange, Reimar Abraham
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (10): 1832–1843.
https://doi.org/10.1158/1535-7163.MCT-18-0048
Published: 01 October 2019
View articletitled, Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity
Open the PDF for Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity in another window
Includes: Supplementary data
Journal Articles

A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model

Tomomi Nakayama Iwata, Chiaki Ishii, Saori Ishida, Yusuke Ogitani, Teiji Wada, Toshinori Agatsuma
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (7): 1494–1503.
https://doi.org/10.1158/1535-7163.MCT-17-0749
Published: 01 July 2018
View articletitled, A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
Open the PDF for A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model in another window
Includes: Supplementary data